FDMT

4D Molecular Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-18

Figures on this page computed 2026-11-08 13:05 UTC

Last close

12.28USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-18

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
-164.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
-128.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
0.04Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.12 against 0.23 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

1,472

2017-12-31 to 2025-12-31100 at the start1,472

Sales: 100.00 on 2017-12-31 to 1471.66 on 2025-12-31, up 1372%.

Shares in issue

390

2017-12-31 to 2025-12-31100 at the start390

Shares in issue: 100.00 on 2017-12-31 to 390.49 on 2025-12-31, up 290%.

Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.

Sales is at 1472, Shares in issue is at 390, against 100 in 2017.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Sales, where the first year is 1001,472
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Profit, where the first year is 100n/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Shares in issue, where the first year is 100391
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself